These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22639401)

  • 41. Sirolimus (rapamycin)-based rescue treatment following chronic rejection after liver transplantation.
    Nishida S; Pinna A; Verzaro R; Levi D; Kato T; Khan F; Nery J; Weppler D; Tzakis A
    Transplant Proc; 2001; 33(1-2):1495. PubMed ID: 11267390
    [No Abstract]   [Full Text] [Related]  

  • 42. The impact of Campath 1H induction in adult liver allotransplantation.
    Tryphonopoulos P; Madariaga JR; Kato T; Nishida S; Levi DM; Moon J; Selvaggi G; De Faria W; Regev A; Bejarano P; Khaled A; Safdar K; Esquenazi V; Weppler D; Yoshida H; Ruiz P; Miller J; Tzakis AG
    Transplant Proc; 2005 Mar; 37(2):1203-4. PubMed ID: 15848669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus?
    Hanto DW; Chudzinski R
    Transplantation; 2009 Jan; 87(2):164-5. PubMed ID: 19155968
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M; Dazzi A; Zanello M; Cucchetti A; Cescon M; Ravaioli M; Del Gaudio M; Lauro A; Grazi GL; Pinna AD
    Transplantation; 2010 Jan; 89(2):227-31. PubMed ID: 20098287
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved results in small bowel transplantation using sirolimus.
    Florman S; Gondolesi G; Schiano T; Tschernia A; LeLeiko N; Kaufman SS; Fishbein T
    Transplant Proc; 2002 May; 34(3):936. PubMed ID: 12034247
    [No Abstract]   [Full Text] [Related]  

  • 46. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection?
    Deuse T; Schrepfer S; Pelletier MP; Fischbein MP; Robbins RC; Reichenspurner H
    Transplant Proc; 2007 Mar; 39(2):569-72. PubMed ID: 17362784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different immunosuppressive effects of liposomal FK506 in liver and kidney transplantation.
    Ko S; Nakajima Y; Kanehiro H; Horikawa M; Yoshimura A; Kido K; Taki J; Aomatsu Y; Kin T; Yagura K; Ohyama T; Ohashi K; Yamada T; Nakano H
    Transplant Proc; 1996 Apr; 28(2):1066-8. PubMed ID: 8623229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Measuring adherence to medications: are complex methods superior to simple ones?
    Shemesh E
    Pediatr Transplant; 2012 Jun; 16(4):315-7. PubMed ID: 22452614
    [No Abstract]   [Full Text] [Related]  

  • 49. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange.
    Yango A; Morrissey P; Monaco A; Butera J; Gohh RY
    Clin Nephrol; 2002 Jul; 58(1):77-8. PubMed ID: 12141412
    [No Abstract]   [Full Text] [Related]  

  • 50. Almost total absence of chronic rejection in primary pediatric liver transplantation under tacrolimus.
    Jain A; Mazariegos G; Pokharna R; Parizhskaya M; Smith A; Kashyap R; Fung JJ; Reyes J
    Transplant Proc; 2002 Aug; 34(5):1968-9. PubMed ID: 12176649
    [No Abstract]   [Full Text] [Related]  

  • 51. De novo use of low-dose tacrolimus and sirolimus in liver transplantation.
    Peltekian K; McAlister VC; Colohan S; Gao Z; Salazar AB; Bitter-Suermann H; MacDonald AS
    Transplant Proc; 2001; 33(1-2):1341. PubMed ID: 11267318
    [No Abstract]   [Full Text] [Related]  

  • 52. Target of rapamycin (TOR) inhibition in renal transplantation: Clinical uses in various populations. Introduction.
    Hricik DE
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S1-2. PubMed ID: 11583937
    [No Abstract]   [Full Text] [Related]  

  • 53. Sirolimus conversion for renal dysfunction in liver transplant recipients: the devil really is in the details….
    McKenna GJ; Trotter JF
    Am J Transplant; 2012 Mar; 12(3):521-2. PubMed ID: 22300457
    [No Abstract]   [Full Text] [Related]  

  • 54. Tacrolimus for prevention of liver allograft rejection: clinical trials and tribulations.
    Morris RE; Brown BW
    Lancet; 1995 Nov; 346(8986):1310-1. PubMed ID: 7475764
    [No Abstract]   [Full Text] [Related]  

  • 55. Invited commentary.
    Bhorade S
    Ann Thorac Surg; 2014 Jan; 97(1):274-5. PubMed ID: 24384177
    [No Abstract]   [Full Text] [Related]  

  • 56. Renal function estimation in cirrhosis.
    Turgut F; Akcay A
    Am J Transplant; 2009 Aug; 9(8):1968. PubMed ID: 19519814
    [No Abstract]   [Full Text] [Related]  

  • 57. The evolving role of sirolimus in renal transplantation.
    Dupont P; Warrens AN
    QJM; 2003 Jun; 96(6):401-9. PubMed ID: 12788958
    [No Abstract]   [Full Text] [Related]  

  • 58. Conversion to sirolimus after kidney and liver transplantation: indications and outcomes.
    Wramner L; Norden G; Herlenius G; Friman S; Olausson M; Bäckman L
    Transplant Proc; 2003 Mar; 35(2):791. PubMed ID: 12644139
    [No Abstract]   [Full Text] [Related]  

  • 59. Sirolimus is coming of age.
    Alexander GJ
    Am J Transplant; 2011 Nov; 11(11):2273-4. PubMed ID: 21967735
    [No Abstract]   [Full Text] [Related]  

  • 60. Foreword.
    Burke GW
    Nephrol Dial Transplant; 2003 May; 18 Suppl 1():i1-2. PubMed ID: 12738755
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.